Tisotumab vedotin is under clinical development by Genmab and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tisotumab vedotin’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 12 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tisotumab vedotin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tisotumab vedotin overview

Tisotumab Vedotin (Tivdak) is a tissue factor-directed antibody-drug conjugate. It is formulated as solution for intravenous use. Tivdak is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Tisotumab vedotin is under development for the treatment of cancers of the cervix, endometrium, bladder, squamous cell carcinoma of the head and neck (SCCHN), castration-resistant prostate cancer, non-small cell lung cancer, epithelial ovarian cancer, Platinum-resistant ovarian cancer, peritoneal cancer, fallopian tube cancer, metastatic colorectal, metastatic and locally advanced solid tumors and pancreatic cancer. It is administered through intravenous route. HuMax-TF is a fully human antibody conjugated targeted to cells expressing CD142 (Tissue Factor or Thromboplastin). HuMax-TF is developed based on ADC technology.

Genmab overview

Genmab is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company’s marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan, and the US. Genmab is headquartered in Copenhagen, Denmark.

Quick View Tisotumab vedotin LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tisotumab vedotin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.